Imazamox-COA-21472-MedChemExpress
香烟烟雾提取物对大鼠肺成纤维细胞生长的影响
香烟烟雾是有众多化学成分的复杂混合物，超过6000种成分，会对肺脏和全身产生有害影响。
吸烟已被公认与多种肺部疾病的发生发展有关，吸烟是肺癌的主要病因，也是慢性阻塞性肺疾病（COPD）等疾病的主要危险因素。
如今，吸烟还被认为与某些间质性肺病及肺纤维化有关[1]，但尚不清楚吸烟引起间质性肺病的发病机制，对吸烟与肺纤维化关系的研究也很少。
为此本研究利用体外培养的正常大鼠及肺纤维化大鼠的肺成纤维细胞，观察不同浓度香烟烟雾提取物（cigarette smoking extract，CSE）对两种细胞的影响，探讨香烟烟雾在肺纤维化中所起的作用。
1 材料与方法1.1 实验材料1.1.1 主要试剂 博来霉素购自天津太河制药有限公司；RPMI-1640培养基、胰蛋白酶、胎牛血清购自美国GIBCO 公司；凋亡检测试剂盒购自美国BD 公司；兔抗大鼠波动蛋白、纤维粘连蛋白、α-平滑肌肌动蛋白（α-SMA）单克隆抗体及SABC 免疫组化试剂盒购自武汉博士德生物工程有限公司、第二抗体为羊抗兔IgG 购自美国Jackson 公司；化学试剂购自美国Sigma 公司。
1.1.2 仪器 二氧化碳培养箱（美国FORMA 公司【摘要】 目的 通过观察不同浓度的香烟烟雾提取物（cigarette smoking extract，CSE）对正常及肺纤维化大鼠肺成纤维细胞的影响，探讨香烟烟雾与肺纤维化的可能关系。
方法 体外培养的正常及博莱霉素造模的肺纤维化大鼠的肺成纤维细胞，分别以不同浓度（25％、50％、100％）的CSE 作用12h 和24h。
噻唑蓝还原法（MTT 法）检测吸光值；流式细胞仪法观察细胞坏死与凋亡情况及细胞周期S 期（DNA 合成期）和G 1期（DNA 合成前期）的比值。
结果 高浓度（100％）的CSE 主要引起两种大鼠肺成纤维细胞的坏死。
较低浓度（25％、50％）的CSE 对正常大鼠肺成纤维细胞无明显影响（P >0.05）。
超声引导下微波消融联合贝伐珠单抗治疗晚期结肠癌伴肝转移的临床价值
·临床研究·超声引导下微波消融联合贝伐珠单抗治疗晚期结肠癌伴肝转移的临床价值韩小军袁理郭道宁摘要目的探讨超声引导下微波消融联合贝伐珠单抗治疗晚期结肠癌伴肝转移的临床应用价值。
方法选取在我院就诊的102例晚期结肠癌伴肝转移患者，按随机数字表法分为观察组和对照组各51例，对照组采用贝伐珠单抗联合常规化疗治疗，观察组在此基础上采用超声引导下微波消融治疗；比较两组患者治疗后疗效、免疫功能、不良反应及预后情况。
结果治疗后，观察组客观缓解率（ORR）、疾病控制率（DCR）均高于对照组（均P<0.05）；两组CD3+、CD4+、CD8+均较治疗前下降，且观察组CD3+、CD4+、CD4+/CD8+均高于对照组，CD8+低于对照组，差异均有统计学意义（均P<0.05）。
治疗后，两组胃肠道反应、食欲减退、疲劳乏力等不良反应比较差异均无统计学意义；观察组累积无复发生存率及累积总生存率分别为78.77%、57.45%，均高于对照组（49.32%、34.23%），差异均有统计学意义（χ2=10.086、4.536，P=0.001、0.033）。
结论超声引导下微波消融联合贝伐珠单抗能提高晚期结肠癌伴肝转移患者的治疗效果，缓解免疫功能抑制，改善生存状况，具有较好的临床应用价值。
关键词超声引导；微波消融；结肠癌，晚期；肝转移；贝伐珠单抗［中图法分类号］R445.1［文献标识码］AClinical value of ultrasound-guided microwave ablation combined withbevacizumab in the treatment of advanced colonadenocarcinoma with liver metastasisHAN Xiaojun，YUAN Li，GUO DaoningDepartment of Ultrasound Medicine，Mianyang Hospital Affiliated to School of Medicine，University of Electronic Science andTechnology of China，Sichuan621000，ChinaABSTRACT Objective To explore the application clinical value of ultrasound-guided microwave ablation combined with bevacizumab in the treatment of advanced colon adenocarcinoma（COAD）with liver metastasis.Methods A total of102 patients with advanced COAD with liver metastasis treated in our hospital were selected，and divided into the observation group and the control group by random number table method，with51cases in each group.The control group was treated with bevacizumab combined with conventional chemotherapy.On this basis，the observation group was treated with ultrasound-guided microwave thermal ablation.The curative effect，immune function，adverse reactions and prognosis after treatment of the two groups were compared.Results After treatment，the objective remission rate（ORR）and disease control rate（DCR）in the observation group were higher than those in the control group（both P<0.05）.After treatment，the CD3+，CD4+and CD4/CD8+in the observation group were higher than those in the control group，and CD8+was lower than that in the control group，the differences were statistically significant（all P<0.05）.After treatment，there were no statistically significant difference in the incidence rates of adverse reactions such as gastrointestinal reactions，loss of appetite and fatigue between the two groups.The cumulative recurrence-free survival rate and cumulative overall survival rate in observation group were78.77%and57.45% respectively，which were significantly higher than those in control group（49.32%and34.23%），the differences were statistically significant（χ2=10.086，4.536，P=0.001，0.033）.Conclusion Ultrasound-guided microwave ablation combined with作者单位：621000四川省绵阳市，电子科技大学医学院附属绵阳医院绵阳市中心医院超声医学科（韩小军、郭道宁），肿瘤科（袁理）通讯作者：郭道宁，Email：******************结肠癌是常见的消化道肿瘤，近年来其发病率和死亡率均逐渐升高。
Imazamox_RP-HPLC_21472_MedChemExpress
4
6
8
GC测定盐酸普拉克索中三乙胺残留量
HMN-214-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Oct.-11-2018Print Date:Oct.-11-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :HMN-214Catalog No. :HY-12045CAS No. :173529-46-91.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4), H302Acute aquatic toxicity (Category 1), H400Chronic aquatic toxicity (Category 1), H4102.2 GHS Label elements, including precautionary statementsPictogramSignal word WarningHazard statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effects.Precautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor ⁄ physician if you feel unwell.P330 Rinse mouth.P391 Collect spillage.P501 Dispose of contents ⁄ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:IVX-214;HMN214;HMN 214;IVX 214;IVX-214;IVX214Formula:C22H20N2O5SMolecular Weight:424.47CAS No. :173529-46-94. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGUN number: 3077Class: 9Packing group: IIIEMS-No: F-A, S-FProper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.Marine pollutant: Marine pollutantIATAUN number: 3077Class: 9Packing group: IIIProper shipping name: Environmentally hazardous substance, solid, n.o.s.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
阿莫西林克拉维酸钾与阿奇霉素配伍用于小儿肺炎的治疗效果及安全性
DOI：10.16662/ki.1674-0742.2023.02.134阿莫西林克拉维酸钾与阿奇霉素配伍用于小儿肺炎的治疗效果及安全性李玉涵新泰市中医医院儿科，山东泰安271200［摘要］目的探讨阿莫西林克拉维酸钾与阿奇霉素配伍用于小儿肺炎的临床价值。
方法便利选取2019年1月—2021年3月新泰市中医医院98例支气管肺炎患儿，随机分为研究组与对照组，每组49例；对照组接受阿奇霉素治疗，研究组接受阿莫西林克拉维酸钾和阿奇霉素治疗。
比较两组的症状改善时间、降钙素原（PCT）、第一秒用力呼气量（FEV1）、白细胞计数（WBC）、血清淀粉样蛋白（SAA）、最大呼气中段流量（MMEF25~75）、第一秒用力呼气量比率（FEV1/FVC）、临床疗效及不良反应。
结果治疗前，两组的FEV1、SAA、MMEF25~75、WBC、PCT、FEV1/FVC比较，差异无统计学意义（P>0.05）；治疗后，研究组的WBC、SAA、PCT低于对照组，FEV1、MMEF25~75、FEV1/FVC高于对照组，差异有统计学意义（P<0.05）；研究组的症状改善时间短于对照组，差异有统计学意义（P<0.05）；研究组总有效率（95.92% vs 79.59%）高于对照组，差异有统计学意义（χ2=6.078，P<0.05）。
结论阿奇霉素与阿莫西林克拉维酸钾配伍治疗能够缩短小儿肺炎患儿治疗时间、改善呼吸道炎症与肺功能，安全性高且治疗效果满意。
［关键词］小儿肺炎；阿莫西林克拉维酸钾；阿奇霉素；肺功能［中图分类号］R816.92 ［文献标识码］A ［文章编号］1674-0742（2023）01(b)-0134-05Therapeutic Effect and Safety of Amoxicillin and Clavulanate Potassium Combined with Azithromycin in Children with PneumoniaLI YuhanDepartment of Pediatrics, Xintai Hospital of Traditional Chinese Medicine, Tai'an, Shandong Province, 271200 China [Abstract] Objective To investigate the clinical value of amoxicillin-clavulanate potassium combined with azithromy⁃cin in children with pneumonia. Methods A total of 98 children with bronchial pneumonia in Xintai Hospital of Tradi⁃tional Chinese Medicine from January 2019 to March 2021 were conveniently selected and randomly divided into a study group and a control group, 49 cases in each group. The control group was treated with azithromycin, and the study group was treated with amoxicillin-clavulanate potassium and azithromycin. The symptom improvement time, procalcitonin (PCT) and forced expiratory volume in one second (FEV1),white blood cell count (WBC), serum amyloid (SAA), maximum mid-expiratory flow (MMEF25~75), forced expiratory volume in the first second (FEV1/FVC) were com⁃pared between the two groups of the clinical efficacy and adverse reactions. Results Before treatment, there was no sta⁃tistically significant difference in FEV1, SAA, MMEF25-75, WBC, PCT, FEV1/FVC between the two groups (P>0.05). After treatment, WBC, SAA, and PCT in the study group were lower than those in the control group, while FEV1, MMEF25~75, and FEV1/FVC were higher than those in the control group, and the difference was statistically significant (P<0.05). The symptom improvement time of the study group was shorter than that of the control group, and the differ⁃ence was statistically significant (P<0.05). The total effective rate of the research group was higher than that of the con⁃trol group (95.92% vs 79.59%), and the difference was statistically significant (χ2=6.078, P<0.05). Conclusion The combined therapy of azithromycin and amoxicillin-clavulanate potassium can shorten the treatment time of children with pneumonia, improve respiratory inflammation and lung function, with high safety and satisfactory therapeutic ef⁃[作者简介] 李玉涵（1978-），女，本科，副主任医师，研究方向为儿内科。
乙酰胆碱酯酶抑制剂
上海应用技术学院研究生课程《高等天然产物化学》试卷2014 / 2015 学年第1 学期课程代码：NX0702013论文题目：乙酰胆碱酯酶抑制剂的研究进展姓名：芮银146061414康满满146061409专业：制药工程学院：化工学院乙酰胆碱酯酶抑制剂的研究进展芮银，陈祎桐，康满满摘要：本文阐述了乙酰胆碱酯酶抑制剂(AChEI)的研究进展，介绍了用于药物治疗的乙酰胆碱酯酶抑制剂的各种来源如植物、微生物等，及其抑制乙酰胆碱的活性物质。
在此基础上，总结了几种现代分析技术，对AChEIs进行筛选，大大加快AD药物资源的开发利用进程。
这些方法主要有基于比色法的Ellman's法及相关的改进方法、薄层显色法、荧光显色法、电喷雾质谱法等。
但是，到目前为止，现代分析技术在AD药物资源中的应用还处在起步阶段。
关键词：乙酰胆碱酯酶抑制剂，筛选方法，薄层显色法，荧光显色法The progress of acetylcholinesteraseinhibitorsRui Yin, Chen Yitong, Kang ManmanAbstract：In this artical, the research elaborates progress of acetylcholinesterase inhibitors (AChEI), and introduces a variety of sources for drug treatment acetylcholinesterase inhibitors such as plants, microorganisms, and its active ingredients. On this basis, the review summarizes several modern analytic techniques such as Ellman's method which based on the colorimetric method, TLC chromogenic method, fluorescent color method, Electrospray ionization mass spectrometry and so on. However, at present, the application of modern analytic techniques in AD drug resources is still in infancy.Key word: Acetylcholinesterase inhibitors, Screening Methods, TLC chromogenic method, Fluorescent color method目录摘要.................................................................................................错误!未定义书签。
API ZYM
2. 试验条的准备
准备一个培养盘和盖子。 记标本号于盘的侧面。 可使用一个塑料挤瓶，分装约 5ml 自来水于培养盘内，为了培养时能保持一定的湿度。 从密封的包装中取出 API ZYM 试验条，臵培养盘内。
3. 试验条的接种 用吸管接种，于试验条的每个杯中接入 2 滴标本(65 微升)。 4. 试验条培养 接种后，托盘上放塑料盖子，一般培养于 370C，4 小时。培养的时间与温度，应取决于所 测样品。不论如何，样品的比较，必需所有的测定条件(时间、温度、培养基、悬液浓度)都要一 致。接种的试验条不能臵有光处。 5. 试验条的结果观察 培养后，加 1 滴 ZYM A 试剂和 1 滴 ZYM B 试剂。 待 5 分钟后生色，如果是阳性，臵试验条于一个强的光源(1000 瓦灯泡) 下 10 秒，放灯 泡于杯的上面 4 秒。 这过程是为消除杯中多余坚牢兰的黄颜色不是反应。 暴光以后阴性反应变 为无色。再臵试验条于日光下几分钟后，就可产生比较的结果。
8.5 6.5 7.5 7.5 7.5 7.5 7.5 8.5 7.5 5.4 5.4 5.4 5.4 5.4 5.4 5.4 5.4 5.4 5.4
紫色 紫色 紫色 紫色 橙色 橙色 橙色 橙色 橙色 紫色 兰色 紫色 紫色 兰色 紫色 紫色 棕色 紫色 紫色 一如果试验 条不放在强 光下，则为 极浅黄色。 一无色或如 果试验条加 入试剂后暴 露在强光下 ，则为对照 的颜色。
1. 多形拟杆菌 B acteroides thetaiotaomicron 2. β -葡萄糖甙酶β-Glucosidase 3. α- 凝乳胰蛋白酶. α-Chymotrypsin
ATCC Sigma Sigma C
API
号 对照 测定的酶
阿西美辛缓释片的制备
科技论坛阿西美辛缓释片的制备解婉茹张磊（哈药集团制药总厂，黑龙江哈尔滨１５００００）阿西美辛（Ａｃｅｍｅｔａｃｉｎ，ＡＭ）是一种新一代非甾体抗炎药，该药抗炎效果显著，镇痛效力强，长期应用对造血系统及全身组织器官均无影响［１］。
因为口服吸收时消除半衰期为２．６小时，所以研制阿西美辛缓释片可以减少服药次数。
本实验研究阿西美辛缓释片的制备方法并建立反相高效液相色谱法测定阿西美辛缓释片中阿西美辛的含量。
1仪器与试药１．１仪器ｗａｔｅｓ２９９６高效液相色谱仪、ｗａｔｅｓ２９９５二极管阵列检测器、梅特勒－托利多分析天平、ＵＶ－９２００紫外分光光度计（北京瑞环分析仪器公司）、ＫＱ－２５０ＤＢ型数控超声波清洗器（昆山市超声仪器有限公司）、ｐＨＳ－２Ｃ型精密酸度计（上海精科雷磁厂）、ＣＤ－１００Ｌ华迪超导热风干燥箱（浙江新昌暖通设备厂）、ＴＨＰ花篮式压片机（上海天祥·健台制药机械有限公司）、智能溶出实验仪（北京卓川电子科技有限公司）；ＺＢ－１Ｃ型智能崩解仪（青岛胜方分析仪器有限公司）；ＹＰＪ－２００Ｂ片剂硬度计（上海黄海药检仪器厂）；ＦＴ－２０００片剂脆碎度检查仪（天津大学无线电厂）。
１．２色谱柱安捷伦十八烷基硅烷键合硅胶色谱柱（２１８×４．６ｍｍ，５μｍ）。
１．３对照品：阿西美辛购自中国药品生物制品检定所。
１．４试剂：甲醇、乙腈为色谱纯；水为纯化水，其它试剂均为分析纯。
2制备方法２．１处方阿西美辛、硬脂酸镁、羟丙基甲基纤维素等。
２．２制备将原料和辅料过８０目筛，混合均匀，乙醇溶液，制湿颗粒，在５５℃烘箱干燥后，整粒，加滑石，混合均匀后压片。
3质量控制３．１性状表面光洁、色泽均匀。
３．２检查重量差异、崩解时限、微生物限度等均符合中国药典２０１０版有关规定。
３．３含量测定３．３．１流动相的选择。
分别考察乙腈一０．０５ｍｏｌ·Ｌ磷酸盐缓冲溶液（磷酸调ＰＨ值为３．０）（４５：５５），甲醇－醋酸盐缓冲液（６０：４０），三乙胺调节ＰＨ至３．５的甲醇－０．２％磷酸溶液（６５：３５）不同比例的流动相，结果以甲醇－醋酸盐缓冲液（６０：４０）为流动相为流动相，供试品各峰分离效果最好，故选用甲醇－醋酸盐缓冲液（６０：４０）为流动相为流动相。